Bisphosphonate‐Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research
By S. Khosla, D. Burr, J. Cauley, D. Dempster, P. Ebeling, D. Felsenberg, R. Gagel, V. Gilsanz, T. Guise, S. Koka and 14 more. Journal of Bone and Mineral Research, 2007
1,652 citations recorded by the source corpus.
Subfields: Nephrology, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/ed3c7f7dd22563a191becaaa23f54197957c2ed9
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Medication-Related Osteonecrosis of the Jaw—2014 Update (2014, background): “J Clin Endocrinol Metab 2007;92(3):1172-1175.”
- The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT) (2011, background): “Although 3- to 4-year trials of bisphosphonates have not identified any consistent safety concerns, several safety concerns have arisen from sources other than trials, including osteonecrosis of the jaw (ONJ),((10)) esophageal cancer, and more recently, atypical femur fractures.”
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (2015, positive): “Side effects of these potent antiresorptives include osteonecrosis of the jaw, atypical subtrochanteric fractures, and hypocalcemia (323,324).”
- 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary (2010, background): “Osteonecrosis of the jaw is defined as an area of exposed alveolar bone in the mandible or maxilla that does not heal after eight weeks.(44) It is extremely rare (< 1 case per 10 000 patient-years among patients with primary osteoporosis).”
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus (2015, neutral): “(1,2) Bisphosphonate (BP)-associated ONJ is defined by the American Society for Bone and Mineral Research (ASBMR) as an area of exposed bone in the maxillofacial region that does not heal within 8 weeks after identification by a health care Received in original form August 26, 2014; revised form Nov”
- Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research (2010, result): “In sharp contrast to prior experience with osteonecrosis of the jaw,((131)) the number of cases of atypical fracture reported in cancer patients receiving high-dose intravenous BPs is substantially lower than those in patients being treated for osteoporosis.”
- Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014, neutral): “The risk of ONJ appears to increase with duration of treatment beyond 5 years [77].”